More stories
Numinus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5,...
VANCOUVER, BC, March 22, 2023 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing...
PT400 – Beckley Retreats: Combining Modern Science, Tradition, and Holistic Wellness
In this episode, Joe interviews the Co-Founder and CEO of Beckley Retreats, Neil Markey. Markey describes Beckley Retreats as comprehensive well-being programs, and talks...
Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023
VANCOUVER, BC, March 21, 2023 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing...
Wesana Health Announces Sale of SANA-13 Assets to Lucy Scientific Discovery
CHICAGO and TORONTO, March 21, 2023 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life...
Psyence Partners with iNGENū for Palliative Care Clinical Trial in Australia
VANCOUVER, British Columbia, March 21, 2023 (GLOBE NEWSWIRE) — Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use...
Algernon Pharmaceuticals Announces Launch of Rights Offering
VANCOUVER, British Columbia, March 21, 2023 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian...
Diamond Therapeutics Announces FDA-authorized Clinical Trial of Low-Dose Psilocybin in Collaboration with University of...
TORONTO, March 21, 2023 /PRNewswire/ – Diamond Therapeutics Inc. (“Diamond”), a drug development company focused on low-dose psychedelic-derived therapies for use in the treatment...
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment...
TORONTO, March 20, 2023 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company...
Psychedelic Bulletin #133: Ketamine Clinics Close with Potential Repercussions for PAT Roll-Out; Psychedelics at...
This Week: and lots more… On Wednesday, the UK’s Chancellor Jeremy Hunt announced the Spring Budget, which sets forth the government’s economic priorities.Among these...
Psychedelics Weekly – Field Trip Health Closes Five Clinics, Legalization Bills Introduced in VT,...
In this episode of Psychedelics Weekly, Joe and Kyle join up once again to discuss the news and articles they found the most interesting...
PT399 – Vital Psychedelic Conversations
In this episode, David hosts another Vital Psychedelic Conversation, this time with Bennet Zelner, Ph.D.: Vital instructor who teaches economics at the University of...
Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use...
Company plans to initiate phase I/IIa in-human clinical trials in Q2 2023 Tel Aviv, Israel / Vancouver, Canada, March 16, 2023 (GLOBE NEWSWIRE) —...
